The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer

The success of the PROfound, IPATential150, and TheraP trials promoted the transition from sequential treatment to therapeutic targets (TTs)‐guided precision treatment in metastatic castration‐resistant prostate cancer (mCRPC). The objective of this study was to evaluate the prevalence and prognosti...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jian Pan, Jinou Zhao, Xudong Ni, Hualei Gan, Yu Wei, Junlong Wu, Tingwei Zhang, Qifeng Wang, Stephen J. Freedland, Beihe Wang, Shaoli Song, Dingwei Ye, Chang Liu, Yao Zhu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2022-12-01
coleção:	Molecular Oncology
Assuntos:	abiraterone HRR metastatic castration‐resistant prostate cancer prognosis PSMA PTEN
Acesso em linha:	https://doi.org/10.1002/1878-0261.13320
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!